Clinical Microbiomics A/S bags €10m financing

Danish microbiome specialist Clinical Microbiomics A/S has completed a €10m growth financing led by - Seventure Partners.

ADVERTISEMENT

The transaction from the Health for Life™ II of the  leading investor in the fast-developing microbiome field

will be used by Clinical Microbiomics to accelerate its development. Specifically, the funds raised will be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand the service offering within multi-omics data integration, as well as to build further presence in key markets starting with the US.

The seven year old company is collabortating with the world’s leading food and consumer health companies and is supporting the pharmaceutical industry in pivotal Phase III studies through its GCP-compliant microbiome research services. Additionanally, the Copenhagen-based company hosts the richest data-warehouse on the market with more than 30,000 samples linking three million bacterial strains to clinical phenotypes.

Microbiome science is widely proposed as the next frontier in addressing our most urgent health challenges. Organisations worldwide are exploring the potential for microbiome science  – from novel nutritional products and next-generation probiotics to new ways to diagnose, treat and prevent disease. 

“Incredible progress has been made in understanding the link between the microbiota and our health in the past years, but there is still much more to be accomplished. There is a lot of data available, but we need better tools to get more insights and standards for how to put it to practice,” said Isabelle de Cremoux, CEO and managing partner at Seventure Partners. “Clinical Microbiomics has a track-record of developing tools that can untangle the complexity of the microbiome and help researchers worldwide understand the mechanisms that impact health and disease. Our investment will enable Clinical Microbiomics to invest even further to lead the way with innovative concepts and services at pharma standards for this field, and we believe their work will play a critical role in unleashing the potential of microbiome science”

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!